Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
  • ASK THE ANALYST
  • Email
  • Print
  • Bookmark
  • Infographic: Scrip 100 Numbers Crunched

    Executive Summary

    This year's Scrip 100 collection is bigger than ever, encompassing 2016 full-year financial data from more than 650 biopharmaceutical companies.

    You may also be interested in...

    

    Scrip 100 Analysis: Impairment, Youth Boost R&D Spending

    Spending on R&D increased substantially in 2016; but the picture is complicated and more than half of the increase is due to accountancy updates following drug program failures, one large company's commitment to new projects, and young companies fuelled by generous financial markets.

    Bayer's Weinand On Pricing, Payers And Pipelines

    Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."

    Adapt Or Die: Sanofi CSO On R&D Challenges Within Unstable Industry

    Sanofi's chief scientific officer Gary Nabel, who joined the company in 2012 from the NIH, discusses R&D challenges for Sanofi and the wider pharma industry, and highlights the company's biggest drug development achievements and toughest moments over the last few years.

    Topics

    UsernamePublicRestriction

    Register

    LL1132999

    Ask The Analyst

    Please Note: Click here for more information on the Ask the Analyst service.

    Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

    All fields are required.

    Please make sure all fields are completed.

    Please make sure you have filled out all fields

    Please make sure you have filled out all fields

    Please enter a valid e-mail address

    Please enter a valid Phone Number

    Ask your question to our analysts

    Cancel
    SC100077

    Email Article

    All set! This article has been sent to my@email.address.

    All fields are required. For multiple recipients, separate email addresses with a semicolon.

    Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.